{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:14:45Z","timestamp":1792808085138,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1001\/jamaoncol.2019.2244","type":"journal-article","created":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T09:30:56Z","timestamp":1559467856000},"page":"1332","source":"Crossref","is-referenced-by-count":227,"title":["Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer\u2014A Phase 1 Study"],"prefix":"10.1001","volume":"5","author":[{"given":"Thomas S.","family":"Uldrick","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"},{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila H.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Lake Success, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Abdul-Hay","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa J.","family":"Claeys","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinda","family":"Emu","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Fling","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith C.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreanne M.","family":"Lacroix","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Lundgren","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center, New Orleans"},{"name":"Pardee Center for Infectious Diseases, University of North Carolina Health Care, Hendersonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharavi","family":"Peeramsetti","sequence":"additional","affiliation":[{"name":"Axio Research, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ching (Jackie)","family":"Wang","sequence":"additional","affiliation":[{"name":"Zuckerberg San Francisco General Hospital, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Cheever","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Cancer Immunotherapy Trials Network, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Cancer Immunotherapy Trials Network (CITN)-12 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"coi190054r1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007.","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"coi190054r2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States.","volume":"123","author":"Engels","year":"2008","journal-title":"Int J Cancer"},{"issue":"7","key":"coi190054r3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/M14-2768","article-title":"Cumulative incidence of cancer among persons with HIV in North America: a cohort study.","volume":"163","author":"Silverberg","year":"2015","journal-title":"Ann Intern Med"},{"issue":"11","key":"coi190054r4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases.","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"coi190054r5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","article-title":"Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.","volume":"28","author":"Morlat","year":"2014","journal-title":"AIDS"},{"issue":"11","key":"coi190054r6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/jamainternmed.2017.4349","article-title":"Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States.","volume":"177","author":"Reddy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"22","key":"coi190054r7","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1200\/JCO.2013.54.8644","article-title":"Cancer treatment disparities in HIV-infected individuals in the United States.","volume":"32","author":"Suneja","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi190054r8","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"issue":"2","key":"coi190054r9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/QAI.0b013e318251aedd","article-title":"A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.","volume":"60","author":"Mosam","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"coi190054r10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/1471-2334-13-471","article-title":"Non-AIDS defining cancers in the D:A:D study\u2014time trends and predictors of survival: a cohort study.","volume":"13","author":"Worm","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"33","key":"coi190054r11","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi190054r12","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"coi190054r13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"9948","key":"coi190054r14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"26","key":"coi190054r15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"coi190054r16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190054r17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7109","key":"coi190054r18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"10","key":"coi190054r19","doi-asserted-by":"publisher","first-page":"e110731","DOI":"10.1371\/journal.pone.0110731","article-title":"CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.","volume":"9","author":"Cockerham","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"coi190054r20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0000000000000314","article-title":"Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease.","volume":"28","author":"Cockerham","year":"2014","journal-title":"AIDS"},{"key":"coi190054r21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3389\/fimmu.2015.00644","article-title":"Dynamic perturbations of the T-cell receptor repertoire in chronic HIV infection and following antiretroviral therapy.","volume":"6","author":"Heather","year":"2016","journal-title":"Front Immunol"},{"issue":"475","key":"coi190054r22","doi-asserted-by":"crossref","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy.","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"coi190054r23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"21","key":"coi190054r24","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy.","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"13","key":"coi190054r25","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2011.39.6853","article-title":"Phase II study of bevacizumab in patients with HIV-associated Kaposi\u2019s sarcoma receiving antiretroviral therapy.","volume":"30","author":"Uldrick","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi190054r26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS).","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"coi190054r27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"coi190054r28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"coi190054r29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"36","key":"coi190054r30","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial.","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi190054r31","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1200\/JCO.2017.35.15_suppl.5514","article-title":"Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study.","volume":"35","author":"Schellens","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10088","key":"coi190054r32","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial.","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"coi190054r33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma.","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi190054r34","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort.","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi190054r35","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma.","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"coi190054r36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/cid\/ciy044","article-title":"As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264\/AMC-067 randomized clinical trial.","volume":"67","author":"Hosseinipour","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"coi190054r37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mdy006","article-title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma.","volume":"29","author":"Delyon","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"coi190054r38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade.","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"coi190054r39","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/QAD.0b013e328360a5a1","article-title":"Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.","volume":"27","author":"Letang","year":"2013","journal-title":"AIDS"},{"issue":"12","key":"coi190054r40","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease.","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med"},{"issue":"24","key":"coi190054r41","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2735517\/jamaoncology_uldrick_2019_oi_190054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T23:12:20Z","timestamp":1663542740000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2735517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.2244","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}